Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXR89M
|
||||
| Drug Name |
1-(4-{3-Methyl-5-[4-(2-phenyl-imidazol-1-yl)-pyrimidin-2-ylamino]-benzyl}-piperazin-1-yl)-ethanone
|
||||
| Synonyms |
CHEMBL46694
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C27H29N7O
|
||||
| Canonical SMILES |
CC(=O)N1CCN(Cc2cc(C)cc(Nc3nccc(n3)n4ccnc4c5ccccc5)c2)CC1
|
||||
| InChI |
InChI=1S/C27H29N7O/c1-20-16-22(19-32-12-14-33(15-13-32)21(2)35)18-24(17-20)30-27-29-9-8-25(31-27)34-11-10-28-26(34)23-6-4-3-5-7-23/h3-11,16-18H,12-15,19H2,1-2H3,(H,29,30,31)
|
||||
| InChIKey |
DSBLOQJREHHYBA-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.